GOTHENBURG, SE / ACCESSWIRE / July 08, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, July 8, 2024 – IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the company will hold a presentation in conjunction with the publication of the interim report for the period January-June 2024. The interim report will be published on Wednesday, July 10 at 07:00 CEST.
The presentation will be held on July 10, 2024, at 10:00 CEST via digital webcast. Gunnar Olsson, CEO, Nicholas Waters, EVP and Head of R&D, and Viktor Siewertz, CFO, will comment the interim report. The presentation will be held in English and will be followed by a Q&A session.
Follow the webcast online: https://www.youtube.com/live/MikgERaXqgY?si=pkoI-inxbEyOx96D
The interim report and the presentation will be available on www.irlab.se , and the recorded version of the presentation will be available shortly afterward.
For more information
Gunnar Olsson, CEO
Phone: +46 70 576 14 02
E-mail: gunnar.olsson@irlab.se
Viktor Siewertz, CFO
Phone: +46 727 10 70 70
E-mail: viktor.siewertz@irlab.se
About IRLAB
IRLAB discovers and develops a portfolio of transformative treatments for all stages of Parkinson’s disease. The company originates from Nobel Laureate Prof Arvid Carlsson’s research group and the discovery of a link between brain neurotransmitter disorders and brain diseases. Mesdopetam (IRL790), under development for treating levodopa-induced dyskinesias, has completed Phase IIb and is in preparation for Phase III. Pirepemat (IRL752), currently in Phase IIb, is being evaluated for its effect on balance and fall frequency in Parkinson’s disease. IRL757, a compound being developed for the treatment of apathy in neurodegenerative disorders, is in Phase I. In addition, the company is also developing two preclinical programs, IRL942 and IRL1117, towards Phase I studies. IRLAB’s pipeline has been generated by the company’s proprietary systems biology-based research platform Integrative Screening Process (ISP). Headquartered in Sweden, IRLAB is listed on Nasdaq Stockholm (IRLAB A). For more information, please visit www.irlab.se .
Attachments
IRLAB: Invitation to the interim report for Q2 2024 presentation and webcast
SOURCE: IRLAB Therapeutics
View the original press release on accesswire.com
View the original press release on accesswire.com
Highlights Continued Progress in Early Detection and the Progression of Esophageal Disease SUFFERN, N.Y., May…
DELRAY BEACH, Fla., May 2, 2025 /PRNewswire/ -- The global Life Science Analytics Market , valued…
LOS ANGELES, May 2, 2025 /PRNewswire/ -- Landmark Science, a premier provider of real-world evidence…
STOCKHOLM, May 2, 2025 /PRNewswire/ -- RaySearch Laboratories AB (publ) is proud to announce that…
The fastest-growing and largest facial membership brand is promoting sun safety and melanoma awareness by…
Integrated system supports methadone dispensing services within a whole-person approach to behavioral healthcare LAKEWAY, Texas,…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
